welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!

Acer jumps on 7-year-old data

Acer Therapeutics Inc. had a welcoming first week on the Nasdaq stock exchange, seeing shares sruge more 10% Monday after verifying positive clinical results published almost seven years ago from a study of celiprolol, the active ingredient in its lead drug candidate.

The study tested celiprolol against placebo in patients with vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening disorder that causes arteries and organs to easily rupture. After receiving treatment for about four years on average, 20% of the participants in the investigational arm experienced arterial events versus 50% of those in the control arm.